検索結果 - Markus A. Seeliger

結果の絞り込み
  1. 1
    Protein Flexibility and Dissociation Pathway Differentiation Can Explain Onset of Resistance Mutations in Kinases**

    Protein Flexibility and Dissociation Pathway Differentiation Can Explain Onset of Resistance Mutations in Kinases** 著者: Mrinal Shekhar, Zachary Smith, Markus A. Seeliger, Pratyush Tiwary

    出版事項 2022
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  2. 2
    Structural Basis for the Recognition of c-Src by Its Inactivator Csk

    Structural Basis for the Recognition of c-Src by Its Inactivator Csk 著者: Nicholas M. Levinson, Markus A. Seeliger, Philip A. Cole, John Kuriyan

    出版事項 2008
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  3. 3
    Activation of tyrosine kinases by mutation of the gatekeeper threonine

    Activation of tyrosine kinases by mutation of the gatekeeper threonine 著者: Mohammad Azam, Markus A. Seeliger, Nathanael S. Gray, John Kuriyan, George Q. Daley

    出版事項 2008
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  4. 4
    A dynamically coupled allosteric network underlies binding cooperativity in Src kinase

    A dynamically coupled allosteric network underlies binding cooperativity in Src kinase 著者: Zachariah H. Foda, Yibing Shan, Eric T. Kim, David E. Shaw, Markus A. Seeliger

    出版事項 2015
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  5. 5
    c-Src Binds to the Cancer Drug Imatinib with an Inactive Abl/c-Kit Conformation and a Distributed Thermodynamic Penalty

    c-Src Binds to the Cancer Drug Imatinib with an Inactive Abl/c-Kit Conformation and a Distributed Thermodynamic Penalty 著者: Markus A. Seeliger, Bhushan Nagar, Filipp Frank, Xiaoxian Cao, Max Henderson, John Kuriyan

    出版事項 2007
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  6. 6
    Catalytic Control in the EGF Receptor and Its Connection to General Kinase Regulatory Mechanisms

    Catalytic Control in the EGF Receptor and Its Connection to General Kinase Regulatory Mechanisms 著者: Natalia Jura, Xuewu Zhang, Nicholas Endres, Markus A. Seeliger, Thomas H. Schindler, John Kuriyan

    出版事項 2011
    全文の入手 全文の入手
    Revisão
    お気に入りに追加
    保存先:
  7. 7
    Survey of solution dynamics in Src kinase reveals allosteric cross talk between the ligand binding and regulatory sites

    Survey of solution dynamics in Src kinase reveals allosteric cross talk between the ligand binding and regulatory sites 著者: Michael Tong, Jeff Pelton, Michelle L. Gill, Weibing Zhang, Francis Picart, Markus A. Seeliger

    出版事項 2017
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  8. 8
    Fibronectin Interaction and Enhancement of Growth Factors: Importance for Wound Healing

    Fibronectin Interaction and Enhancement of Growth Factors: Importance for Wound Healing 著者: Katarzyna M. Sawicka, Markus A. Seeliger, Tagai Musaev, Lauren K. Macri, Richard A.F. Clark

    出版事項 2015
    全文の入手
    Revisão
    お気に入りに追加
    保存先:
  9. 9
    How Does a Drug Molecule Find Its Target Binding Site?

    How Does a Drug Molecule Find Its Target Binding Site? 著者: Yibing Shan, Eric T. Kim, Michael P. Eastwood, Ron O. Dror, Markus A. Seeliger, David E. Shaw

    出版事項 2011
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  10. 10
    A conserved mechanism of DEAD-box ATPase activation by nucleoporins and InsP6 in mRNA export

    A conserved mechanism of DEAD-box ATPase activation by nucleoporins and InsP6 in mRNA export 著者: Ben Montpetit, N.D. Thomsen, Kara J. Helmke, Markus A. Seeliger, James M. Berger, Karsten Weis

    出版事項 2011
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  11. 11
    Highly specific, bisubstrate-competitive Src inhibitors from DNA-templated macrocycles

    Highly specific, bisubstrate-competitive Src inhibitors from DNA-templated macrocycles 著者: George P. Georghiou, Ralph E. Kleiner, Michael J. Pulkoski‐Gross, David R. Liu, Markus A. Seeliger

    出版事項 2012
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  12. 12
    High yield bacterial expression of active c‐Abl and c‐Src tyrosine kinases

    High yield bacterial expression of active c‐Abl and c‐Src tyrosine kinases 著者: Markus A. Seeliger, Matthew A. Young, Max Henderson, Patricia Pellicena, David S. King, Arnold M. Falick, John Kuriyan

    出版事項 2005
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  13. 13
    A Novel In Vitro CypD-Mediated p53 Aggregation Assay Suggests a Model for Mitochondrial Permeability Transition by Chaperone Systems

    A Novel In Vitro CypD-Mediated p53 Aggregation Assay Suggests a Model for Mitochondrial Permeability Transition by Chaperone Systems 著者: Ivan Lebedev, Alice Nemajerová, Zachariah H. Foda, Maja Kornaj, Michael Tong, Ute M. Moll, Markus A. Seeliger

    出版事項 2016
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  14. 14
    Organization of the SH3-SH2 Unit in Active and Inactive Forms of the c-Abl Tyrosine Kinase

    Organization of the SH3-SH2 Unit in Active and Inactive Forms of the c-Abl Tyrosine Kinase 著者: Bhushan Nagar, Oliver Hantschel, Markus A. Seeliger, Jason M. Davies, William I. Weis, Giulio Superti‐Furga, John Kuriyan

    出版事項 2006
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  15. 15
    Three Different Binding Sites of Cks1 Are Required for p27-Ubiquitin Ligation

    Three Different Binding Sites of Cks1 Are Required for p27-Ubiquitin Ligation 著者: Danielle Sitry, Markus A. Seeliger, Tun Kiat Ko, Dvora Ganoth, Sadie E Breward, Laura S. Itzhaki, Michele Pagano, Avram Hershko

    出版事項 2002
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  16. 16
    What Makes a Kinase Promiscuous for Inhibitors?

    What Makes a Kinase Promiscuous for Inhibitors? 著者: Sonya M. Hanson, George P. Georghiou, Manish Thakur, W. Todd Miller, Joshua S. Rest, John D. Chodera, Markus A. Seeliger

    出版事項 2019
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  17. 17
    Equally Potent Inhibition of c-Src and Abl by Compounds that Recognize Inactive Kinase Conformations

    Equally Potent Inhibition of c-Src and Abl by Compounds that Recognize Inactive Kinase Conformations 著者: Markus A. Seeliger, Pratistha Ranjitkar, Corynn Kasap, Yibing Shan, David E. Shaw, Neil P. Shah, John Kuriyan, Dustin J. Maly

    出版事項 2009
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  18. 18
    Substrate-selective inhibitors that reprogram the activity of insulin-degrading enzyme

    Substrate-selective inhibitors that reprogram the activity of insulin-degrading enzyme 著者: Juan Pablo Maianti, G.A. Tan, Amedeo Vetere, A.J. Welsh, Bridget K. Wagner, Markus A. Seeliger, David R. Liu

    出版事項 2019
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  19. 19
    A novel activating, germline JAK2 mutation, JAK2R564Q, causes familial essential thrombocytosis

    A novel activating, germline JAK2 mutation, JAK2R564Q, causes familial essential thrombocytosis 著者: S. Leah Etheridge, Megan E. Cosgrove, Veena Sangkhae, Lana Corbo, Michelle E. Roh, Markus A. Seeliger, Edward K. L. Chan, Ian S. Hitchcock

    出版事項 2013
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  20. 20
    A conserved protonation-dependent switch controls drug binding in the Abl kinase

    A conserved protonation-dependent switch controls drug binding in the Abl kinase 著者: Yibing Shan, Markus A. Seeliger, Michael P. Eastwood, Filipp Frank, Huafeng Xu, Morten Ø. Jensen, Ron O. Dror, John Kuriyan, David E. Shaw

    出版事項 2008
    全文の入手
    Artigo
    お気に入りに追加
    保存先:

検索ツール: